CRISPR Therapeutics Vertex Pharmaceuticals: Better Buy in 2026
Investors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Combining total market funds with international funds in retirement can create a diversified, tax-efficient portfolio with smoother growth.
28,507 articlesInvestors face a choice between a high-growth gene-editing bet and a cash-generating biotech leader. This article bre...
Active ETFs are reshaping how people think about investing. This article explains what they are, when they can beat p...
Could this chip stock be the next Micron? As AI workloads surge, memory players with strong contract pipelines and he...
Immersed, a private VR work platform behind the work-from-VR trend, is closing its under-$1 retail round. Early metri...
A top market analyst says the popular rotation narrative is flawed. New ETF flow data show bitcoin didn’t lose gold, ...
Bitcoin holds near $67K as traders pile into downside protection in the options market, signaling caution amid a chop...
A disciplined foundation reshapes its tech-payments exposure by boosting its stake in Shift4 Payments. This article e...
A prominent asset manager has quietly ramped up its Bitcoin exposure, even as its massive stash remains underwater. T...
February brought an 11% slide in main street capital stock as investors weighed private credit risk and rising rates....
A telecom giant surprised investors with a sharp month-long rally. This article breaks down the factors behind Verizo...
Start your weekend with a clear read on the investing landscape. This Friday Reads collection distills practical idea...
C3.AI stock has shed shares in 2026, but that drop raises the question: is this a buying opportunity or a trap? This ...